Gilead Sciences' primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), has been shown to diminish a key marker of ...
The Chosun Ilbo on MSN
Genetox completes phase 3, targets 2027 approval
Genetox, a latecomer in the botulinum toxin market, has completed the administration and follow-up observation of subjects in ...
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...
Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced encouraging results from its Phase 2b clinical ...
Immune checkpoint inhibitors (CPIs) have transformed cancer treatment, but resistance and limited response rates have driven ...
(9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific ...
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA ...
Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...
Rivia Expands Clinical Trial Intelligence Platform with New AI-Powered Data Findings Module New module enables continuous, automated review of clinical trial data, helping drug developers identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results